PCSK9 and metabolic dysfunction-associated steatotic liver disease: Given that PCSK9 plays a pivotal role in cholesterol regulation and is a known driver of cardiovascular disease (CVD), it has been speculated that PCSK9 is implicated in non-alcoholic fatty liver disease (NAFLD) which shows similar pathogenesis and pathological spectra to ALD and an increased risk of CVD.